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Abstract
Introduction: Myopathies can be sub-classified into congenital, hereditary, mitochondrial, and
secondary myopathies.
Congenital myopathies are usually diagnosed post partal or in early childhood. Manifestation in
adolescence is uncommon and most cases occur as sporadic mutations. Therefore, there is a risk
of under diagnosing this disease in middle-aged patients showing pain, dysfunction, recurrent
trauma or falls, where muscle atrophy is seen as a secondary injury.
Case presentation: Our report is about a 54 year old Caucasian woman with an extended
history of pain, loss of function and weakness in her right shoulder. The clinical picture showed a
frozen right shoulder. The main finding was a marked limb-muscle atrophy of both delta- und
biceps-muscles and a rotator cuff tear that had developed over years. Previous medical
consultations attributed the atrophy to recurrent falls, shoulder dysfunction and pain. Conservative
treatment (analgesics, physiotherapy, training) had failed.
The familiar anamnesis was free of any neurological diseases or other genetic diseases.
MRI showed a sub-total proximal muscular limb atrophy and a rotator cuff tear in both shoulders.
An incision-biopsy of the right delta- and biceps-muscle revealed a chronical myopathy. The level
of creatinkinasis was expected to be high but measurements showed values only slightly above
normal. Immunohistochemistry, eventually revealed a mild form of LGMD (type 2I). Due to the
pattern of symptoms and diagnostic results we described the case as atypical LGMD.
Conclusion: Our case presents a phenotype of a late onset of limb girdle muscular dystrophy
syndrome associated with shoulder pain and dysfunction and recurrent falls. This kind of disease is
not very common. In particular, muscle atrophy in the elderly is generally seen as a secondary
injury. This case should remind us of the importance of a differential diagnosis of a late onset of
muscular dystrophy-syndrome in the elderly, since an early diagnosis offers more treatment
options, therefore preventing a rapid progression.
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Introduction
Muscular atrophy, occurring very often in connection
with bone and joint diseases, is very common in the eld-
erly and can have different causes.
A main cause is the reduced use of muscles or muscle
groups, for example around a painful joint. Nerve injury
or dysfunction causes neurogenic atrophy to the related
muscles. Inflammation can also cause muscle atrophy as
well as other secondary disorders of muscles, following
general organic diseases like metabolic, endocrine,
ischemic, vascular, toxic and paraneoplastic myopathies.
Primary myopathies can be classified in congenital, hered-
itary, mitochondrial, and progressive muscular dystro-
phy-syndromes [1-3].
Congenital myopathies are usually diagnosed post partal
or in early childhood. Manifestation in adolescence is
uncommon [1]. Therefore there is a risk of underdiagnos-
ing this differential diagnosis, if the atrophy is hidden or
explained by other symptoms. Pain, recurrent falling, and
dysfunction may mislead physicians to interpret muscle
atrophy as a secondary symptom.
This rare case of a very late diagnosed myopathy high-
lights the importance of differential diagnosis. Regarding
the simple diagnostic steps (clinical picture, MRI, serum
CK, biopsy) myopathy should always be kept in mind by
all medical departments treating bone and joint diseases.
Case presentation
The 54 year old Caucasian woman, who came to our clinic
for the first time in September 2006, complained of pain,
loss of function and weakness in her right shoulder. She
had suffered from these symptoms for years. Conservative
treatment by analgesics and physiotherapy showed little
or no benefit. Her main reason for coming to our hospital
was an increasing loss of function of her right shoulder. In
addition she reported several unexplained falls but no
feeling of waddling gait and hypotonia. She had oste-
oporotic vertebral compression fractures at thoracic level
5 and 6. The corresponding thoracic gibbus was compen-
sated by hyperlordosis of the lumbar spine. After a traffic
accident in 2004, she was treated conservatively for a frac-
ture of the right scapula and the sternum. She sometimes
felt dysaesthesia in both hands. She casually referred to
progressive muscle atrophy in both shoulders and upper
arms, which other doctors had assigned to previous
trauma and inactivity. The familiar anamnesis of her two
sons was negative, without signs of neurological or sys-
temic diseases. There was no intellectual impairment or
facial weakness.
The patient's clinical examination showed no signs of car-
diac or pulmonary impairment. There was a frozen right
shoulder, a pronounced isolated limb-muscle atrophy of
the delta- und biceps-muscle on both sides and a rotator
cuff tear of the supraspinatus and infraspinatus muscle on
the right side 1, 2 and 3. There were no signs of muscle
impairment in the hip or thigh. The clinical neurological
examination revealed a normal result. Walking analysis
showed no waddling gait.
In view of the pronounced muscle atrophy of both shoul-
ders, that was progressive over years, despite physiother-
apy, a myopathy was suspected although it seemed
unlikely in a middle-aged patient.
Contrary to the expected high increase of the level of
serum creatinkinasis, the level of serum creatinkinasis was
only slightly above normal (186 U/l). The exact pattern
[1] of muscle atrophy was detected by a MRI [2] of both
shoulders which showed a fatty muscular atrophy of the
delta- und biceps-muscle on both sides and a rotator cuff
tear on the right.
Anterolateral view to the right arm of the patient Figure 1
Anterolateral view to the right arm of the patient. The scar 
results from the incision biopsy. Look at the obvious atrophy 
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Despite the slightly increased serum creatinkinasis and
the symmetric atrophy of identical muscles pointing to a
muscular dystrophy of the limb girdle type [1], the diag-
nosis needed further examination using light microscopy
and immunohistochemistry of affected muscles. There-
fore we performed an incision biopsy of the right delta-
and biceps-muscle to ensure diagnosis. The different sam-
ples were kept in formaline, in kryo-fixation, and before
being embedded in plastic, in glutaraldehyde.
The results of the immuno-histological (Table 1) analysis
matched a chronical myopathy with related endo-, peri-
and epimysial fibrosis. Trauma and inflammation were
excluded as causes.
Further analysis (western blot) revealed an abnormal and
reduced laminin α2 chain and an abnormal reduced α-
dystroglycan. These findings allow a diagnosis of
LGMD2I, where a secondary reduction of laminin-a2 on
immunolabelling was detected in most cases and a reduc-
tion in α-dystroglycan may also be seen.
We discussed treatment options with the patient. Beside a
conservative treatment with muscle training a cortisone
therapy was recommended to prevent or slow down fur-
ther progression. The patient refused a cortisone treat-
ment due to the risk of adverse effects.
Discussion
The typical pattern of a symmetric muscular atrophy of
both shoulder girdles as well as the immuno-histochemi-
cal analyses point to a muscle-dystrophic process. Based
on our analyses we think that we found a case of a late
onset and mild form of LGMD2I. The patient's history
makes this case worth publishing. Even though she only
showed some symptoms of LGMD, the clinical pattern of
muscle atrophy is typical. The immunohistochemistrial
changes are also seen in the rarer conditions LGMD2K, 2L
and 2N reflecting the common pathological feature of a
loss of glycosylation of alpha dystroglycan in this group
[2].
The appearance of the disease in this case has to be dis-
cussed.
The onset of LGMD 2I occurs between the age of 0.5 to 27
years (61% < 5) [1]. The age of onset may vary both
between and within subtypes and even between patients
with the same mutation. There is an early onset in teenage
years and a later onset, with slower progress and only
some non-ambulant patients (28%), in the 4th to 6th dec-
ades [4,5]. Late manifestation has also been described in
LGMD 1A, 1C and is very unlikely in the other forms of
LGMD [2,6-8].
Respiratory involvement and failure is common in LGMD
2I, as well as cardiac involvement [2], but was not seen in
our case. Overnight pulse oximetry, if the FVC is <60%,
annual influenza vaccination and prompt treatment of
respiratory infections are recommended [1.6,9] with res-
piratory involvement.
Patients can develop secondary contractures in LGMD 2I,
whereas other forms of LGMD have no contractures or
primary contractures (LGMD 1B, 2A). The finding of a fro-
zen shoulder may partially be an effect of the disease but
it can also be caused by an independent process.
Frontal view of the patient with a manifest reduction of  upper arm muscles Figure 2
Frontal view of the patient with a manifest reduction of 
upper arm muscles.
The dorsal view also shows the marked atrophy of the upper  arms Figure 3
The dorsal view also shows the marked atrophy of the upper 
arms.Cases Journal 2008, 1:402 http://www.casesjournal.com/content/1/1/402
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Serum CK mirrors the amount of muscle destruction.
Depending on the type of LGMD, CK is not elevated or
only slightly elevated (< 5× upper limit of normal at
LGMD 1A, 1B), elevated (5× to 10× upper limit of normal
at LGMD 1C, 2A, 2C-F, 2I) or highly elevated (>10× upper
limit of normal at LGMD 2B and also 1C, 2A, 2C-F, 2I)
[10]. Hence, we expected a high elevation of CK in our
patient. The comparably marginal increase of CK may
reflect a low disease activity. It has to be underlined that
low or normal CK levels do not exclude a LGMD [1,2].
Leading clinical symptoms of LGMD are weakness with a
waddling gait, difficulty in stair-climbing and hypotonia.
Weakness is more proximal than distal in arms and legs.
Thigh adductors, psoas and quadriceps muscle are usually
affected in the lower limbs. The periscapular muscles, del-
toid, biceps and triceps muscle are typically involved in
the upper limbs. There was a mild facial weakness in some
patients described [1,2,5,6]. In our case, we found typical
symptoms that had developed over years. Maybe the coin-
cidence of several falls and shoulder pain prompted the
therapists to classify the muscle atrophy as secondary. A
muscle disease or muscle atrophy was not considered up
to that point.
Further diagnostics using DNA analysis were discussed.
DNA analysis, aimed at providing confirmation of muta-
tion in the affected gene(s), is necessary to be able to offer
carrier or pre-symptomatic testing to other family mem-
bers [2,11,12]. We discussed this topic with the patient
and her sons but they declined further DNA analysis. An
early diagnosis, even in mild forms with the late onset,
may improve chances of treatment and outcome. How-
ever, there are no established drug treatments for the
LGMD. Creatine monohydrate and co-enzyme Q10 (ubi-
quinone) were tested but not under controlled conditions
[2,3] and corticosteroids have been used empirically in
some patients with LGMD2C-F with reported improve-
ment [13]. Preclinical studies are working on gene transfer
and stem cell transplantation [14].
Conclusion
Late onset and mild manifestation of LGMD 2I in the
middle-aged patient is uncommon. Irrespective of the typ-
ical pattern of muscle atrophy, there is a high risk of
underdiagnosis, particularly if other parameters like
serum CK levels and clinical signs (intellectual impair-
ment, facial weakness) are inconspicuous. The potential
benefit of an early therapy LGMD in the elderly, has to be
kept in mind.
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CD: cluster of differentiation; CK: serum-creatinkinasis;
DNA: deoxyribonucleic acid; HE-staining: Hematoxylin
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Nicotinamide adenine dinucleotide dehydrogenase tetra-
Table 1: Results of light microscopy and immunohistochemistry
Toluidin-blue and HE-staining Focally accentuated chronic myopathy with endo-, peri- and epimyseal 
fibrosis, reduced fiber thickness and augmentation of endomysial 
connective tissue
Trichrome-staining Focal subsarcolemmal fuchsinophily, centralised cores
PAS-staining Regular content of muscle-glycogene
Elastica-von-gieson and oil-red-staining No amyloid
NADH-TR-enzymeimmunohistochemistry Normal forming of groups of type I and II muscles, predominance of type 
I muscle fibers
Immunohistochemistry for myofiber-ATPasis (3 diff. pH's) Mainly type-I-muscle-fibers/also type-II muscle-fibers had central 
encymatic defects
Succinatedehydrogenasis and cytochrome-c-oxidasis activity Normal
Lead-citrate and uranyl-acetate cuts Muscle-fibers with subsarcolemmal deposited triglycerides and dilatated 
vacuoles, internal structure partially loosened
Antibodies anti-dystrophine-epitopes 1, 2 and 3 and anti-ubiquitine, 
merosin, desmine and alpha-sarcoglycane
Regular colouring
Antibodies anti LCS, CD 3 and CD 20 Normal number of mononuclear cellsPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Cases Journal 2008, 1:402 http://www.casesjournal.com/content/1/1/402
Page 5 of 5
(page number not for citation purposes)
zolium reductase; PAS-staining: Periodic acid-Schiff stain-
ing.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SM: Manuscript, clinical evaluation, surgery, TP: Manu-
script, clinical evaluation. QM: Manuscript, literature
review, all the authors read and approved the final manu-
script.
Acknowledgements
We would like to thank Prof. Pagenstecher (Marburg, Germany) and Prof. 
J. Weis (Aachen, Germany) for substantial contribution, concerning their 
helpful comments and immunohistochemical analysis.
References
1. Emery AE: The muscular dystrophies.  BMJ 317(7164):991-5.
1998 Oct 10
2. Norwood F, de VM, Eymard B, Lochmulle r H, Bushby K: EFNS
guideline on diagnosis and management of limb girdle mus-
cular dystrophies.  Eur J Neurol 2007, 14(12):1305-12.
3. Angelini C: Limb-girdle muscular dystrophies: heterogeneity
of clinical phenotypes and pathogenetic mechanisms.  Acta
Myol 2004, 23(3):130-6.
4. Balci B, Uyanik G, Dincer P, Gross C, Willer T, Talim B, et al.: An
autosomal recessive limb girdle muscular dystrophy
(LGMD2) with mild mental retardation is allelic to Walker-
Warburg syndrome (WWS) caused by a mutation in the
POMT1 gene.  Neuromuscul Disord 2005, 15(4):271-5.
5. Brockington M, Blake DJ, Prandini P, Brown SC, Torelli S, Benson MA,
et al.: Mutations in the fukutin-related protein gene (FKRP)
cause a form of congenital muscular dystrophy with second-
ary laminin alpha2 deficiency and abnormal glycosylation of
alpha-dystroglycan.  Am J Hum Genet 2001, 69(6):1198-209.
6. Kirschner J, Bonnemann CG: The congenital and limb-girdle
muscular dystrophies: sharpening the focus, blurring the
boundaries.  Arch Neurol 2004, 61(2):189-99.
7. Bonnemann CG: Limb-girdle muscular dystrophy in childhood.
Pediatr Ann 2005, 34(7):569-77.
8. Bushby KM: The limb-girdle muscular dystrophies-multiple
genes, multiple mechanisms.  Hum Mol Genet 1999,
8(10):1875-82.
9. Mathews KD, Moore SA: Limb-girdle muscular dystrophy.  Curr
Neurol Neurosci Rep 2003, 3(1):78-85.
10. Eagle M: Report on the muscular dystrophy campaign work-
shop: exercise in neuromuscular diseases Newcastle, Janu-
ary 2002.  Neuromuscul Disord 2002, 12(10):975-83.
11. Weilbach FX, Kress W, Strassburg HM, Muller CR, Gold R: [Cur-
rent diagnosis in muscular dystrophies. New developments,
methods of examination and case examples].  Nervenarzt 1999,
70(2):89-100.
12. Guglieri M, Magri F, Comi GP: Molecular etiopathogenesis of
limb girdle muscular and congenital muscular dystrophies:
boundaries and contiguities.  Clin Chim Acta 2005, 361(1–
2):54-79.
13. Moxley RT III, Ashwal S, Pandya S, Connolly A, Florence J, Mathews
K, et al.:  Practice parameter: corticosteroid treatment of
Duchenne dystrophy: report of the Quality Standards Sub-
committee of the American Academy of Neurology and the
Practice Committee of the Child Neurology Society.  Neurol-
ogy 64(1):13-20. 2005 Jan 11
14. Daniele N, Richard I, Bartoli M: Ins and outs of therapy in limb
girdle muscular dystrophies.  Int J Biochem Cell Biol 2007,
39(9):1608-24.